Control Bionics (ASX: CBL) 進軍美國運動表現與日本神經復健市場

Control Bionics (ASX: CBL) 已將其先進的 NeuroStrip 無線穿戴裝置的第一份商業協議擴展到美國運動表現和日本神經復健市場。

Control Bionics (ASX:CBL) has announced the first commercial agreements for its advanced NeuroStrip wireless wearable device, expanding into the US sports performance and Japanese neurological rehabilitation markets.

Control Bionics (ASX:CBL) 宣布了其先進 NeuroStrip 無線穿戴裝置的第一份商業協議，該設備將擴展到美國運動表現和日本神經復健市場。

These strategic partnerships will leverage Control Bionics' technology to drive better sports performance and patient outcomes, while also serving as platforms for expanding into other regions.

這些策略合作夥伴關係將利用 Control Bionics 的技術來提高運動表現和患者治療效果，同時也作為擴展到其他地區的平台。

The company expects the agreements to diversify its market focus and generate material revenue through hardware sales of NeuroStrip and recurring software-as-a-service (SaaS) subscription fees.

該公司預計這些協議將使其市場重點多元化，並透過 NeuroStrip 的硬體銷售和經常性軟體即服務 (SaaS) 訂閱費產生實質收入。

Neuro Elite Athletics dealThe first commercial deal is with US-based Neuro Elite Athletics (NEA), where Control Bionics will acquire a 20% stake for a US$250,000 consideration, including cash and in-kind contributions.

Neuro Elite Athletics 交易第一個商業交易是與美國 Neuro Elite Athletics (NEA) 達成的，Control Bionics 將以 250,000 美元的價格收購其 20% 的股份，其中包括現金和實物捐助。

This investment is expected to rapidly accelerate the rollout of NEA's proprietary NeuroBounce jump improvement program, which is initially targeting domestic markets.

這項投資預計將迅速加速 NEA 專有的 NeuroBounce 跳躍改進計劃的推出，該計劃最初針對國內市場。

The program is described as the world's only computerised electromyography (EMG) training solution proven to increase an athlete's vertical leap by as much as 15 centimetres and enhance explosiveness in just a few sessions.

該計劃被描述為世界上唯一的電腦化肌電圖 (EMG) 訓練解決方案，經證明只需幾次訓練即可將運動員的垂直彈跳提高多達 15 公分並增強爆發力。

College focusNeuroBounce is being targeted to the more than 28,500 sports teams and 600,000 athletes on the lucrative US college circuit.

大學焦點NeuroBounce 的目標客戶是利潤豐厚的美國大學巡迴賽中的 28,500 多個運動隊和 600,000 名運動員。

NEA also plans to market the program to more than 300,000 high school teams nationwide with 7.9 million participants, presenting long-term growth potential for Control Bionics.

NEA 還計劃向全國超過 30 萬個高中團隊推廣該項目，共有 790 萬名參與者，為 Control Bionics 帶來長期成長潛力。

Under the terms of the NEA acquisition, Control Bionics will receive direct revenue from hardware sales, software subscriptions and its share of NeuroBounce distributions.

根據 NEA 收購條款，Control Bionics 將從硬體銷售、軟體訂閱以及 NeuroBounce 發行版中獲得直接收入。

It will also have exclusive rights to market NeuroBounce in Australia and Japan.

它還將擁有 NeuroBounce 在澳洲和日本的獨家行銷權。

Stroke Lab agreementControl Bionics has also signed an agreement with Tokyo-based rehabilitation facility Stroke Lab to localise NeuroStrip technology for the Japanese market.

中風實驗室協議Control Bionics 也與東京復健機構中風實驗室簽署了一項協議，將 NeuroStrip 技術本地化到日本市場。

The facility combines neurology and therapy to deliver evidence-based, personalised care and has proven expertise in surface EMG technology for stroke recovery.

該機構將神經病學和治療結合起來，提供循證的個人化護理，並在中風復健的表面肌電圖技術方面擁有經過驗證的專業知識。

The deal establishes a framework for a joint operating agreement in the new year that will strengthen Control's foothold in Japan's advanced rehabilitation market.

該交易為新的一年的聯合營運協議建立了框架，這將加強 Control 在日本先進復健市場的立足點。

Pivotal stepControl Bionics chief executive officer Jeremy Steele said the new commercial agreements mark a pivotal step in the company’s mission to harness neurotechnology for human empowerment.

Pivotal stepControl Bionics 執行長 Jeremy Steele 表示，新的商業協議標誌著該公司利用神經技術增強人類使命的關鍵一步。

“These collaborations underscore our ability to enter and lead high-growth markets and drive innovation while delivering value for our shareholders,” he said.

他表示：“這些合作凸顯了我們進入並引領高成長市場、推動創新、同時為股東創造價值的能力。”

“By strengthening our relationships with existing customers we have the opportunity to more rapidly scale our company, diversifying into new markets and generating recurring revenue to build a business that has a very promising future.”

“透過加強與現有客戶的關係，我們有機會更快地擴大公司規模、多元化進入新市場並產生經常性收入，從而建立一個前景光明的業務。”